Ascend Capital’s Alpine Immune Sciences Inc ALPN Stock Holding History

Ascend Capital’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-37,500	Closed	-$690K	–	171
2016 Q2	$690K	Buy	37,500 +25,000	+200%	+$444K	0.05%	135
2016 Q1	$208K	Buy	+12,500	New	+$250K	0.02%	93
2015 Q4	–	Sell	-2,974	Closed	-$156K	–	177
2015 Q3	$156K	Buy	+2,974	New	+$195K	0.01%	120

Other funds holding ALPN

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ascend Capital's ALPN Position: Q3 2016 in Review

Ascend Capital sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2016, closing a stake of 37,500 shares — an estimated $690K sold.

Ascend Capital first reported a position in ALPN in Q3 2015 and held it in 3 quarters. The position peaked at $690K in Q2 2016. 50 funds tracked by Wall St. Rank hold ALPN as of Q3 2016.

Ascend Capital reported no remaining Alpine Immune Sciences Inc position as of Q3 2016 after selling out during the quarter.
Ascend Capital sold 37,500 Alpine Immune Sciences Inc shares in Q3 2016, an estimated $690K.
Ascend Capital first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 3 quarters.
Ascend Capital's Alpine Immune Sciences Inc position peaked at $690K in Q2 2016.
50 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2016.

Based on Ascend Capital's 13F filing for Q3 2016, filed 14 Nov 2016.